How to treat behavioral symptoms in a dementia patient already on medication?

Treatment of Behavioral Symptoms in Dementia Patients Already on Medication

Prioritize non-pharmacological interventions first, and only add or adjust medications when behaviors are severe, dangerous, or causing imminent risk of harm to self or others after behavioral approaches have been systematically attempted and documented as insufficient. 1, 2

---

Step 1: Systematically Investigate Underlying Medical Causes

Before adjusting any medications, aggressively search for and treat reversible medical triggers that commonly drive behavioral symptoms in dementia patients who cannot verbally communicate discomfort 1:

• Pain assessment and management - This is a major contributor to behavioral disturbances and must be addressed before considering psychotropic adjustments 1
• Infections - Check for urinary tract infections, pneumonia, and other infections 1
• Metabolic derangements - Evaluate for dehydration, electrolyte imbalances, hypoxia 2
• Constipation and urinary retention - Both frequently trigger agitation 1, 2
• Medication review - Identify and discontinue anticholinergic medications (diphenhydramine, oxybutynin, cyclobenzaprine) that worsen agitation and cognitive function 2
• Sensory impairments - Address hearing and vision problems that increase confusion and fear 1

---

Step 2: Implement Intensive Non-Pharmacological Interventions

These approaches have substantial evidence for efficacy without the mortality risks associated with pharmacological treatment and must be attempted before medication adjustments 1, 2:

Environmental Modifications 1

• Ensure adequate lighting and reduce excessive noise
• Install safety equipment (grab bars, bath mats, remove hazardous objects)
• Simplify the environment with clear labels and structured layouts
• Provide adequate task lighting

Communication Strategies 1

• Use calm tones and simple one-step commands instead of complex multi-step instructions
• Allow adequate time for the patient to process information before expecting response
• Use gentle touch for reassurance rather than harsh or confrontational approaches
• Avoid open-ended questioning that increases confusion

Caregiver Education and Support 1

• Educate caregivers that behaviors are symptoms of dementia, not intentional actions
• Help establish a "new normal" routine that prioritizes patient safety and well-being over pre-dementia standards
• Teach ABC charting (Antecedent-Behavior-Consequence) to identify specific triggers
• Time care activities when the patient is most calm and receptive

Activity and Routine 1

• Provide meaningful activities tailored to the patient's interests and abilities
• Establish structured daily routines
• Simplify tasks into manageable steps

---

Step 3: Determine If Medication Adjustment Is Warranted

Psychotropic medications should only be added or adjusted in three specific circumstances 1:

1. Major depression with or without suicidal ideation
2. Psychosis causing harm or with great potential of harm
3. Aggression causing imminent risk to self or others

Important caveat: Psychotropics are unlikely to impact unfriendliness, poor self-care, memory problems, inattention, repetitive verbalizations/questioning, rejection of care, shadowing, or wandering 1. Do not prescribe medications for these symptoms.

---

Step 4: Medication Selection Algorithm (Only After Steps 1-3)

For Chronic Agitation Without Psychotic Features

First-line: SSRIs 1, 2, 3

• Citalopram: Start 10 mg/day, maximum 40 mg/day 2, 3
• Sertraline: Start 25-50 mg/day, maximum 200 mg/day 2, 3
• Assess response at 4 weeks using quantitative measures (Cohen-Mansfield Agitation Inventory or NPI-Q) 2
• If no clinically significant response after 4 weeks at adequate dose, taper and discontinue 1, 2

Second-line: Trazodone (if SSRIs fail or not tolerated) 2

• Start 25 mg/day, maximum 200-400 mg/day in divided doses
• Use caution in patients with premature ventricular contractions due to orthostatic hypotension risk 2

For Severe Agitation With Psychotic Features or Aggression

Only when patient is severely agitated, threatening substantial harm to self or others, and behavioral interventions have failed 1, 2:

Risperidone (preferred based on most recent evidence) 2, 3, 4

• Start 0.25 mg once daily at bedtime
• Increase by 0.25 mg increments every 5-7 days as tolerated
• Target dose: 0.5-1.25 mg daily, maximum 2 mg daily 3
• Provides modest benefits for aggression (SMD -0.22), psychosis (SMD -0.23), and anxiety/phobias (SMD -0.19) 4
• Monitor for extrapyramidal symptoms at doses >2 mg/day 2
• Week 2 response predicts week 8 improvement (OR 4.46) - if no response by week 2, strongly consider discontinuation 4

Alternative: Quetiapine 2, 5

• Start 12.5 mg twice daily, maximum 200 mg twice daily
• More sedating with higher risk of orthostatic hypotension 2
• Less likely to cause extrapyramidal symptoms than risperidone 2

For Acute Dangerous Agitation Requiring Immediate Intervention

Haloperidol (only for emergency situations) 2

• 0.5-1 mg orally or subcutaneously, maximum 5 mg daily in elderly
• Use lowest effective dose for shortest duration possible
• Evaluate need daily with in-person examination 2

---

Critical Safety Requirements Before Starting Any Antipsychotic

You must discuss the following with the patient (if feasible) and surrogate decision maker 2:

• Increased mortality risk (1.6-1.7 times higher than placebo) 2
• Cardiovascular effects including QT prolongation, dysrhythmias, sudden death 2
• Risk of falls, pneumonia, metabolic changes 2
• Expected benefits (which are modest at best: SMD -0.21) 5, 4
• Treatment goals and plans for ongoing monitoring 2
• Alternative non-pharmacological approaches 2

---

Step 5: Monitoring and Reassessment

• Evaluate response within 4 weeks using the same quantitative measure used at baseline 2
• Monitor for side effects: extrapyramidal symptoms, falls, sedation, metabolic changes, QT prolongation, cognitive worsening 2
• Daily in-person examination to evaluate ongoing need when using antipsychotics 2
• Taper and discontinue if no clinically meaningful benefit after adequate trial 1, 2
• Do not continue antipsychotics indefinitely - review need at every visit 1, 2

---

Special Considerations for Cholinesterase Inhibitors and Memantine

Do NOT discontinue cholinesterase inhibitors if the patient currently has clinically meaningful psychotic symptoms, agitation, or aggression until these symptoms have stabilized 1. Patients who have had clinically meaningful reduction in neuropsychiatric symptoms with cognitive enhancers should continue treatment even if there is cognitive and functional decline 1.

---

What NOT to Do

• Avoid typical antipsychotics (haloperidol, fluphenazine, thiothixene) as first-line therapy due to 50% risk of tardive dyskinesia after 2 years of continuous use 2
• Avoid benzodiazepines for routine use - they increase delirium incidence and duration, cause paradoxical agitation in 10% of elderly patients, and carry risks of tolerance, addiction, and cognitive impairment 2
• Do not use anticholinergic medications (diphenhydramine) - they worsen agitation and cognitive function 2
• Do not prescribe antipsychotics for mild agitation - reserve for severe, dangerous symptoms only 2
• Patients over 75 years respond less well to antipsychotics, particularly olanzapine 1, 2